Yui Yamashita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yui Yamashita has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Naotetsu Kanamoto
Department of Endocrinology, Osaka City General Hospital , Osaka 534-0021
3 shared publications - Kazuwa Nakao
Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan
2 shared publications - Keiko Yamagami
Department of Internal Medicine, Osaka City General Hospital, Osaka, Japan
2 shared publications - Akihiro Yasoda
Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication - Daisuke Taura
Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine , Kyoto 606-8507
1 shared publication Eri Kondo
Departments of Diabetes, Endocrinology, and Nutrition (E.K., A.Y., T.F., Y.Y., Y.U.-S., N.K., M.M., N.I.) and Maxillofacial Surgery (Kazum. N.) and Medical Innovation Center (Kazuw. N.), Kyoto University Graduate School of Medicine, 606-8507 Kyoto, Japan; Health Care Service Center (H.A.), Kyoto Institute of Technology, Matsugasaki-Hashikami-cho, 606-8585 Kyoto, Japan; and Department of Nephrology (M.K.), Graduate School of Medical Science, Kumamoto University, 860-8556 Kumamoto City, Japan
1 shared publication
Latest Publications
- Open Access
- 29 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (6)
Sonography of thyroid involvement in Langerhans cell histiocytosis
- 29 April 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (6)
Open AccessSonography of thyroid involvement in Langerhans cell histiocytosis
- Open Access
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (9) , EJ26-0108-1079
Anti–pituitary-specific transcription factor-1 hypophysitis developing after thymoma resection: a case report with review of literature
Anti–pituitary-specific transcription factor-1 (PIT-1) hypophysitis is an acquired autoimmune disorder characterized by selective deficiencies of growth hormone (GH), prolactin (PRL), and thyrotropin (TSH). It is typically driven by ectopic PIT-1 expression in thymomas or other malignancies, and in previously reported cases, thymectomy has been shown to attenuate autoimmunity. In contrast, we report a novel case that developed after thymectomy. A 42-year-old woman with normal preoperative thyroid function underwent resection of a WHO type B2 thymoma. Eleven months later, she developed specific deficiencies of GH, PRL, and TSH. The diagnosis of anti–PIT-1 hypophysitis was confirmed by the presence of serum anti-PIT-1 antibodies and PIT-1–reactive cytotoxic T lymphocytes. Immunohistochemistry revealed ectopic PIT-1 expression in the resected tumor. Replacement therapy with levothyroxine and recombinant human GH was initiated. Serum FT4 and IGF-1 levels subsequently improved to normal. Two-year post-thymectomy chest computed tomography revealed no tumor recurrence. This unique clinical course challenges the conventional view that the presence of the tumor alone is sufficient to drive autoimmunity. Instead, it suggests a multifactorial pathogenesis requiring the convergence of ectopic antigen expression, genetic predisposition, and a potential trigger. We hypothesize that thymectomy itself acted as the trigger disrupting immune tolerance, potentially through immunogenic cell death or alterations in the immune milieu. This case highlights anti–PIT-1 hypophysitis as a potential post-thymectomy autoimmune complication and that central hypothyroidism should be considered in patients presenting with nonspecific symptoms after thymectomy. Further research is needed to delineate risk factors for susceptibility and to develop preventive strategies.
- 1 January 2026
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 73 (9) , EJ26-0108-1079
Open AccessAnti–pituitary-specific transcription factor-1 hypophysitis developing after thymoma resection: a case report with review of literature
Anti–pituitary-specific transcription factor-1 (PIT-1) hypophysitis is an acquired autoimmune disorder characterized by selective deficiencies of growth hormone (GH), prolactin (PRL), and thyrotropin (TSH). It is typically driven by ectopic PIT-1 expression in thymomas or other malignancies, and in previously reported cases, thymectomy has been shown to attenuate autoimmunity. In contrast, we report a novel case that developed after thymectomy. A 42-year-old woman with normal preoperative thyroid function underwent resection of a WHO type B2 thymoma. Eleven months later, she developed specific deficiencies of GH, PRL, and TSH. The diagnosis of anti–PIT-1 hypophysitis was confirmed by the presence of serum anti-PIT-1 antibodies and PIT-1–reactive cytotoxic T lymphocytes. Immunohistochemistry revealed ectopic PIT-1 expression in the resected tumor. Replacement therapy with levothyroxine and recombinant human GH was initiated. Serum FT4 and IGF-1 levels subsequently improved to normal. Two-year post-thymectomy chest computed tomography revealed no tumor recurrence. This unique clinical course challenges the conventional view that the presence of the tumor alone is sufficient to drive autoimmunity. Instead, it suggests a multifactorial pathogenesis requiring the convergence of ectopic antigen expression, genetic predisposition, and a potential trigger. We hypothesize that thymectomy itself acted as the trigger disrupting immune tolerance, potentially through immunogenic cell death or alterations in the immune milieu. This case highlights anti–PIT-1 hypophysitis as a potential post-thymectomy autoimmune complication and that central hypothyroidism should be considered in patients presenting with nonspecific symptoms after thymectomy. Further research is needed to delineate risk factors for susceptibility and to develop preventive strategies.
- 1 October 2017
- Published by Elsevier in Neuropeptides
- Vol. 65, 10-20
Neuronal cells derived from human induced pluripotent stem cells as a functional tool of melanocortin system
- 1 October 2017
- Published by Elsevier in Neuropeptides
- Vol. 65, 10-20
Neuronal cells derived from human induced pluripotent stem cells as a functional tool of melanocortin system
- Open Access
- 10 April 2015
- Published by The Endocrine Society in Endocrinology
- Vol. 156 (7) , 2518-2529
Increased Bone Turnover and Possible Accelerated Fracture Healing in a Murine Model With an Increased Circulating C-Type Natriuretic Peptide
Recent studies have revealed that C-type natriuretic peptide (CNP) is a potent stimulator of endochondral bone growth. Nevertheless, the effect of CNP on bone turnover has not yet been well studied. To elucidate this issue, we investigated the bone phenotype of a mouse model with elevated plasma CNP concentrations (SAP-CNP-Tg mice) in the present study. Microcomputed tomography (CT) analysis revealed less bone in femurs, but not in lumber vertebrae, of young adult SAP-CNP-Tg mice than that of wild-type mice. Bone histomorphometry of the tibiae from 8-week-old SAP-CNP-Tg mice showed enhanced osteoblastic and osteoclastic activities, in accordance with elevated serum levels of osteocalcin and tartrate-resistant acid phosphatase-5b, respectively. Next we performed an open and stabilized femoral fracture using 8-week-old SAP-CNP-Tg mice and compared the healing process with age-matched wild-type mice. An immunohistochemical study revealed that CNP and its receptors, natriuretic peptide receptor-B and natriuretic peptide clearance receptor, are expressed in hard calluses of wild-type mice, suggesting a possible role of CNP/natriuretic peptide receptor-B signaling in fracture repair, especially in bone remodeling stage. On micro-CT analysis, a rapid decrease in callus volume was observed in SAP-CNP-Tg mice, followed by a generation of significantly higher new bone volume with a tendency of increased bone strength. In addition, a micro-CT analysis also showed that bone remodeling was accelerated in SAP-CNP-Tg mice, which was also evident from increased serum osteocalcin and tartrate-resistant acid phosphatase-5b levels in SAP-CNP-Tg mice at the remodeling stage of fracture repair. These results indicate that CNP activates bone turnover and remodeling in vivo and possibly accelerates fracture healing in our mouse model.
- 10 April 2015
- Published by The Endocrine Society in Endocrinology
- Vol. 156 (7) , 2518-2529
Open AccessIncreased Bone Turnover and Possible Accelerated Fracture Healing in a Murine Model With an Increased Circulating C-Type Natriuretic Peptide
Recent studies have revealed that C-type natriuretic peptide (CNP) is a potent stimulator of endochondral bone growth. Nevertheless, the effect of CNP on bone turnover has not yet been well studied. To elucidate this issue, we investigated the bone phenotype of a mouse model with elevated plasma CNP concentrations (SAP-CNP-Tg mice) in the present study. Microcomputed tomography (CT) analysis revealed less bone in femurs, but not in lumber vertebrae, of young adult SAP-CNP-Tg mice than that of wild-type mice. Bone histomorphometry of the tibiae from 8-week-old SAP-CNP-Tg mice showed enhanced osteoblastic and osteoclastic activities, in accordance with elevated serum levels of osteocalcin and tartrate-resistant acid phosphatase-5b, respectively. Next we performed an open and stabilized femoral fracture using 8-week-old SAP-CNP-Tg mice and compared the healing process with age-matched wild-type mice. An immunohistochemical study revealed that CNP and its receptors, natriuretic peptide receptor-B and natriuretic peptide clearance receptor, are expressed in hard calluses of wild-type mice, suggesting a possible role of CNP/natriuretic peptide receptor-B signaling in fracture repair, especially in bone remodeling stage. On micro-CT analysis, a rapid decrease in callus volume was observed in SAP-CNP-Tg mice, followed by a generation of significantly higher new bone volume with a tendency of increased bone strength. In addition, a micro-CT analysis also showed that bone remodeling was accelerated in SAP-CNP-Tg mice, which was also evident from increased serum osteocalcin and tartrate-resistant acid phosphatase-5b levels in SAP-CNP-Tg mice at the remodeling stage of fracture repair. These results indicate that CNP activates bone turnover and remodeling in vivo and possibly accelerates fracture healing in our mouse model.